Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis
A Randomized, Double-blind, Controlled, Clinical Food Study to Evaluate the Effect of KB174 Compared to an Easily Digestible Polysaccharide on Function and Structure of the Gut Microbiome in Subjects With Well-compensated Cirrhosis
Sponsor: Kaleido Biosciences
Listed as NCT03855956, this NA trial focuses on Early Cirrhosis and remains completed. Sponsored by Kaleido Biosciences, it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2020 — Jan 2021 [monthly]
Completed NA
Status: Recruiting → Completed
-
Feb 2020 — Jun 2020 [monthly]
Recruiting NA
▶ Show 3 earlier versions
-
May 2019 — Feb 2020 [monthly]
Recruiting NA
-
Apr 2019 — May 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Apr 2019 [monthly]
Not Yet Recruiting NA
First recorded
Feb 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kaleido Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .